We will deliver:
- A mechanism to facilitate concerted interaction between an European Community (EC) core activity and European Union (EU) Member States' investments
- A mechanism to accelerate the process of bringing promising research results, i.e. experimental vaccines for diseases of poverty, via limited industrial production to clinical evaluation in European volunteers; and subsequent clinical evaluation in close collaboration with clinical research networks in disease endemic areas.
EVI aims to position ourselves as the 'European Vaccine Development Agency' for diseases of poverty and be recognised as such by all stakeholders. EVI aims to bridge the gap between bench product, further validation and limited production with clinical testing, to facilitate industrial development and production.
The specific objectives of EVI are:
- To fund research and development, including clinical trials, with a supra-national focus
- To create a conducive technical and financial environment in which potential vaccines for diseases of poverty can be brought to clinical trials in humans, linking together research, education and training, development, manufacturing and clinical development expertise from both European and disease endemic countries
- To improve the flow of information between the European scientific community, partners in Developing Countries, relevant organisations/institutions, and vaccine manufacturers (private and public), in order to facilitate co-operation
- To provide a forum and networks to enhance general and political awareness of the importance of controlling diseases of poverty
- To provide a forum for the EC and EU Member States’ Research and Development Ministries/Agencies for consultation on the role and development of vaccines for diseases of poverty in the wider context of disease control.